A phase 3 randomized, multi-center, double-blind, placebo-controlled, parallel-group, multiple dose safety and efficacy study of epinastine nasal spray vs. placebo in subjects with seasonal allergic rhinitis.

Trial Profile

A phase 3 randomized, multi-center, double-blind, placebo-controlled, parallel-group, multiple dose safety and efficacy study of epinastine nasal spray vs. placebo in subjects with seasonal allergic rhinitis.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs Epinastine (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 20 May 2011 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 23 Apr 2008 Status changed from in progress to discontinued, as reported by Inspire Pharmaceuticals in a company media release.
    • 23 Apr 2008 Inspire Pharmaceuticals reported in a media release that this trial failed to meet it's primary endpoint. Subsequently development of epinastine nasal spray is to be discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top